Menu Search
Equities

Algorae Pharmaceuticals Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
LHI0:FRA

Algorae Pharmaceuticals Ltd

Actions
  • Price (EUR)0.01
  • Today's Change-0.001 / -4.76%
  • Shares traded10.00k
  • 1 Year change+400.00%
  • Beta0.4574
Data delayed at least 15 minutes, as of Feb 13 2026 07:09 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Algorae Pharmaceuticals Limited is an Australia-based artificial-intelligence (AI) enabled pharmaceutical development company. The Company’s proprietary AI platform, Algorae Operating System (AlgoraeOS), is an AI platform that leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. Its other drug candidates include AI-116, AI-168, NTCELL. AI-116 is a combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease. AI-168 is a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient, which is conceptualized to be a potential treatment for cardiovascular disease, including hypertension. NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells.

  • Revenue in AUD (TTM)141.05k
  • Net income in AUD-802.96k
  • Incorporated2003
  • Employees--
  • Location
    Algorae Pharmaceuticals LtdLevel 23,, Rialto South Tower,,525 Collins Street,MELBOURNE 3000AustraliaAUS
  • Phone+61 30028-8664
  • Fax+61 41793-5552
  • Websitehttps://algoraepharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.